Future oncology (London, England)

publication venue for

Pleural effusion in a patient with metastatic gastrointestinal stromal tumor treated with imatinib: case report. 2014
Patient preferences for attributes of bispecific antibodies for relapse/refractory diffuse large B-cell lymphoma in the US. 2025
EA1211: interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy (DIRECT trial). 2025
A plain language summary of the TROPHY-U-01 study (Cohort 2): use of sacituzumab govitecan after immunotherapy in people with metastatic urothelial cancer who cannot take cisplatin-based chemotherapy.. 21. 2025
A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML. 2025
A multi-perspective study assessing Black and African American participation barriers in prostate cancer clinical trials.. 21. 2025
Safety of pressurized intraperitoneal aerosolized chemotherapy in biliary cancer patients with peritoneal metastases.. 20. 2024
The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with KIT exon 11 + 17/18 mutations.. 20. 2024
A plain language summary of the TROPHY-U-01 study: sacituzumab govitecan use in people with locally advanced or metastatic urothelial cancer.. 20. 2024
Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment.. 19. 2023
Which traits affect how long patients with advanced prostate cancer live when treated with enzalutamide?. 18. 2022
T cell-inflamed gene expression profile and PD-L1 expression and pembrolizumab efficacy in advanced esophageal cancer. 2022
Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC.. 18. 2021
KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma.. 17. 2021
Prognostic implications of depression and inflammation in patients with metastatic lung cancer.. 17. 2020
Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer.. 17. 2020
First-line immunotherapy versus targeted therapy in patients with BRAF-mutant advanced melanoma: a real-world analysis.. 17. 2020
Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases.. 16. 2020
KEYNOTE-676: Phase III study of BCG and pembrolizumab for persistent/recurrent high-risk NMIBC.. 16. 2020
Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer.. 16. 2019
KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer.. 15. 2019
Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale.. 15. 2019
A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale.. 13. 2016
Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia.. 12. 2016
A case for the use of receiver operating characteristic analysis of potential clinical efficacy biomarkers in advanced renal cell carcinoma.. 12. 2015
Desmoplastic small round cell tumor 20 years after its discovery.. 11. 2015
Best of International Stereotactic Radiosurgery Society Congress 2013: stereotactic body radiation therapy. Part I: spinal tumors.. 9. 2013
Best of International Stereotactic Radiosurgery Society Congress 2013: stereotactic body radiation therapy. Part II: nonspinal tumors.. 9. 2013
Adipose-derived stem cells promote lymphangiogenesis in response to VEGF-C stimulation or TGF-β1 inhibition.. 7. 2011
Long-term benefit of sotorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: plain language summary.. 20. 2023
Prolonging the life of people with metastatic breast cancer in routine clinical practice by adding palbociclib to an aromatase inhibitor from a real-world database analysis: a plain language summary.. 19. 2023
Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial. 2022
Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer. 2022
A global approach to inflammatory breast cancer. 2011
Nanomolecular targeting of dendritic cells for ovarian cancer therapy.. 5. 2009
Tumor microenvironment of metastasis (TMEM): a novel tissue-based assay for metastatic risk in breast cancer.. 5. 2009
Talking to patients about biosimilars. 2018
Nodal metastases in thyroid cancer: prognostic implications and management. 2016
Current advances in targeted therapies for metastatic gastric cancer: improving patient care. 2016
Imaging assessment of tumor response: past, present and future. 2011
High-risk prostate cancer: the role of radical prostatectomy for local therapy. 2011
Fatty acid synthase as a potential therapeutic target in cancer. 2010
Diffusion-weighted imaging in head and neck cancers. 2009
Prostate cancer: psychosocial implications and management. 2008
Current and future surgical approaches in the management of endometrial carcinoma. 2008
Treatment options in hormone-sensitive prostate cancer: targeting the androgen-sensitive pathway. 2025
Focal therapy for oligometastatic and oligoprogressive renal cell carcinoma: a narrative review. 2024
Cerebrospinal fluid-administered therapies for leptomeningeal metastases from solid tumors. 2023
Plain language summary: Can declines in prostate-specific antigen level indicate how long patients with advanced prostate cancer will live when treated with enzalutamide? 2023
Enzalutamide, an oral androgen receptor inhibitor for treatment of castration-resistant prostate cancer. 2019
Androgen deprivation therapy with chemotherapy or abiraterone for patients with metastatic hormone-naive prostate cancer: a systematic review and meta-analysis. 2019
Nivolumab and ipilimumab: immunotherapy for treatment of malignant melanoma. 2018
Immune checkpoint blockade in advanced hepatocellular carcinoma: an update and critical review of ongoing clinical trials. 2018
A critical review on ramucirumab in the treatment of advanced urothelial cancer. 2017
Treatment of soft tissue sarcoma: a focus on earlier stages. 2017
Imaging of local recurrence in prostate cancer. 2016
Novel approaches to imaging basal cell carcinoma. 2015
Role of MRI in the diagnosis and management of prostate cancer. 2015
Radiation-induced coronary artery disease: a second survivorship challenge? 2015
Emerging applications of stereotactic body radiotherapy. 2014
Tissue engineering and regeneration of lymphatic structures. 2013
Stereotactic body radiation therapy for prostate cancer. 2011
Predictive markers of colorectal cancer liver metastases. 2011
Dose-dense chemotherapy for breast cancer: what does the future hold? 2010
Critical review of prostate cancer predictive tools. 2009
Roles of LPA in ovarian cancer development and progression. 2009
Clinical states model for biomarkers in bladder cancer. 2009
Satraplatin for the therapy of castration-resistant prostate cancer. 2009
Update on nuclear medicine imaging of neuroendocrine tumors. 2009
Percutaneous renal cryoablation: current status. 2008
Blood biomarkers for prostate cancer detection and prognosis. 2007
The role of p53 mutations as a prognostic factor and therapeutic target in inflammatory breast cancer. 2006
Targeting HER1/EGFR in cancer therapy: experience with erlotinib. 2005

VIVO Weill Cornell Medical College

Future oncology (London, England) Journal

Overview

publication venue for

Identity

ISO Abbreviation

Linking ISSN

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)